Baird Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $104

BioMarin Pharmaceutical Inc. -0.16% Pre

BioMarin Pharmaceutical Inc.

BMRN

57.41

57.41

-0.16%

0.00% Pre
Baird analyst Joel Beatty maintains Biomarin Pharmaceutical (NASDAQ: BMRN) with a Outperform and lowers the price target from $127 to $104.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via